Companion Diagnostic Technologies Market is Expected to Hit $ 3.5 billion by 2020: Development Factors and Investment Analysis By Top Players

According to a study by Allied Market Research, the world companion diagnostic market is expected to reach $ 3.5 billion by 2020 and is expected to grow at an average CAGR of 20% between 2014 and 2020.

Helper Diagnosis (CD) is an in vitro diagnostic technique that provides information about the patient's response to a specific treatment. Companion diagnosis helps identify patients who can benefit from a particular treatment, resulting in better treatment outcomes and lower health care spending. CD can also help identify patient pools that are most responsive to treatment. Therefore, we exclude therapies that are not effective. It also reduces costs by protecting patients from side effects caused by ineffective therapy. As the incidence of cancer increases and the side effects of drugs and personalized therapies increase, research and development efforts are under way to focus on the development of targeted therapies.

The technological advances and discoveries of new biomarkers are also driving the growth of this market. However, coordinating co-diagnosis and therapeutic development is a challenge for this market. Nonetheless, significant investments have been made in the research and development of targeted therapies that require companion diagnostics due to increased cancer, cardiovascular disease, and central nervous system and which may be opportunities for growth in this market.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/135

The accompanying diagnostic diagnostics market is divided into oncology, cardiovascular, CNS, autoimmune & inflammation, virology and others. Currently, the vast majority of companion diagnostics are developed for cancer, so it is a major revenue generating segment in the entire CD display market. Companion diagnosis has been developed for breast cancer, lung cancer, colorectal cancer, stomach cancer and melanoma.

Companion diagnosis for breast cancer is the most common breast cancer incidence because of the increased incidence of breast cancer and the development of many companion diagnoses to detect HER / neu biomarkers for breast cancer. Currently, there is little or no accompanying diagnosis for cardiovascular disease, central nervous system conditions, inflammation and autoimmune diseases and viral diseases, and most of them are in the development stage. However, as more and more biomarkers are discovered, the development of new companion diagnostics will increase.

Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/135

The technology-specific companion diagnostic market is divided into immunohistochemistry and molecular diagnostics. Molecular diagnostics is the most preferred technology, and next-generation sequencing and real-time PCR are expected to drive growth in this market due to advances in these technologies.

The market is followed by North America and Europe due to significant improvements in medical awareness, significant investment in research and development, and an increase in cancer and other disease incidence in the region.

However, LAMEA is expected to increase at a significant rate due to the increased incidence of cancer in this region. There is also a growing awareness of medical care in the region. The use of companion diagnostics will therefore continue to increase.
The ten major companies dealing with companion diagnostics are profiled, such as Qiagen, Dako (Agilent Technologies), Roche, Abbott Laboratories, Inc., bioMerieux, Ventana Medical Systems, Myriad Genetics, Inc., Leica Microsystems, Resonance Health Ltd, . The key strategy most companies follow is working with pharmaceutical companies to develop companion diagnostics for pipeline drugs.

Access Full Summery @ https://www.alliedmarketresearch.com/companion-diagnostic-technologies-market

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:

David Correa

5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States

Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975

help@alliedmarketresearch.com

This release was published on openPR.